Maximum Medical Therapy: Brinzolamide/Brimonidine And Travoprost/Timolol Fixed-Dose Combinations In Glaucoma And Ocular Hypertension

References

• Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ. 2005;331(7509):134. doi:10.1136/bmj.38506.594977.E0
   PubMed Web of Science ®Google Scholar
• AGISInvestigators T. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS investigators. Am J Ophthalmol. 2000;130(4):429–440.
   Web of Science ®Google Scholar
• Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013;120(3):512–519.
   Web of Science ®Google Scholar
• EGS. European glaucoma society terminology and guidelines for glaucoma, 4th Edition - Chapter 3: treatment principles and options supported by the egs foundation: part 1: foreword; introduction; glossary; chapter 3 treatment principles and options. Br J Ophthalmol. 2017;101(6):130–195.
   Web of Science ®Google Scholar
• Law SK. First-line treatment for elevated intraocular pressure (IOP) associated with open-angle glaucoma or ocular hypertension: focus on bimatoprost. Clin Ophthalmol. 2007;1(3):225–232.
   PubMedGoogle Scholar
• Eyawo O, Nachega J, Lefebvre P, et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009;3:447–456.
   PubMedGoogle Scholar
• Li F, Huang W, Zhang X. Efficacy and safety of different regimens for primary open-angle glaucoma or ocular hypertension: a systematic review and network meta-analysis. Acta Ophthalmol. 2018;96(3):e277–e284.
   Web of Science ®Google Scholar
• Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging. 2007;24(12):1007–1016.
   PubMed Web of Science ®Google Scholar
• Crawley L, Zamir SM, Cordeiro MF, Guo L. Clinical options for the reduction of elevated intraocular pressure. Ophthalmol Eye Dis. 2012;4:43–64.
   PubMedGoogle Scholar
• Fechtner RD, Singh K. Maximal glaucoma therapy. J Glaucoma. 2001;10(5 Suppl 1):S73–75. doi:10.1097/00061198-200110001-00026
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol. 2004;15(2):132–135. doi:10.1097/00055735-200404000-00013
   PubMedGoogle Scholar
• Zimmerman TJ, Fechtner RD. Maximal medical therapy for glaucoma. Arch Ophthalmol. 1997;115(12):1579–1580. doi:10.1001/archopht.1997.01100160749014
   Google Scholar
• EMA. <duotrav-epar-product-information_en.pd.pdf>. 2019. Available from: https://wwwemaeuropaeu/en/documents/product-information/duotrav-epar-product-information_enpdf. Accessed August 26, 2019.
   Google Scholar
• Jordao ML, Hatanaka M, Ogundele A, de Moraes Silva MR, Vessani RM. Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy. Clin Ophthalmol. 2014;8:1527–1534. doi:10.2147/OPTH
   Google Scholar
• Schnober D, Hubatsch DA, Scherzer ML. Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy. Clin Ophthalmol. 2015;9:825–832. doi:10.2147/OPTH.S80880
   PubMed Web of Science ®Google Scholar
• Nakano T, Mizoue S, Fuse N, Iwase A, Matsumoto S, Yoshikawa K. Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: a prospective multicenter open-label study. Adv Ther. 2015;32(9):823–837. doi:10.1007/s12325-015-0246-9
   Web of Science ®Google Scholar
• Simbrinza EMA Summary of Product Characteristics. 2019. Available from: https://wwwemaeuropaeu/documents/product-information/simbrinza-epar-product-information_enpdf. Accessed August 26, 2019
   Google Scholar
• Feldman RM, Katz G, McMenemy M, Hubatsch DA, Realini T. A randomized trial of fixed-dose combination brinzolamide 1%/brimonidine 0.2% as adjunctive therapy to travoprost 0.004. Am J Ophthalmol. 2016;165:188–197. doi:10.1016/j.ajo.2016.02.026
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Myers JS, Hubatsch DA, Budenz DL, DuBiner HB. Ocular hypotensive effect of fixed-combination brinzolamide/brimonidine adjunctive to a prostaglandin analog: a randomized clinical trial. Eye (Lond). 2016;30(10):1343–1350. doi:10.1038/eye.2016.126
   Web of Science ®Google Scholar
• Denis F, Andrew R, Wells D, Friren B. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol. 2006;16(3):407–415. doi:10.1177/112067210601600308
   Web of Science ®Google Scholar
• Suic SP, Laus KN, Dosen VM, Ekert M, Mandic Z, Bojic L. Comparison of evening and morning dosing of travoprost 0.004%/timolol 0.5% fixed combination in 6 month period. Coll Antropol. 2010;34(3):847–852.
   Google Scholar
• Pfeiffer N, Scherzer ML, Maier H, et al. Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy. Clin Ophthalmol. 2010;4:459–466. doi:10.2147/opth.s10694
   PubMedGoogle Scholar
• Costa VP, Moreira H, Paolera MD. de Moraes Silva MR. Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy. Clin Ophthalmol. 2012;6:699–706. doi:10.2147/OPTH.S30717
   Google Scholar
• Lerner SF, Park KH, Hubatsch DA, Erichev V, Paczka JA, Roberts TV. Efficacy and tolerability of travoprost 0.004%/timolol 0.5% fixed-dose combination for the treatment of primary open-angle glaucoma or ocular hypertension inadequately controlled with beta-blocker monotherapy. J Ophthalmol. 2017;2017:1917570.
   PubMed Web of Science ®Google Scholar
• Whitson JT, Realini T, Nguyen QH, McMenemy MG, Goode SM. Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053–1060. doi:10.2147/OPTH.S46881
   PubMedGoogle Scholar
• Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348–2355. doi:10.1016/j.ophtha.2014.06.022
   Web of Science ®Google Scholar
• Gandolfi SA, Lim J, Sanseau AC, Parra Restrepo JC, Hamacher T. Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31(12):1213–1227.
   PubMed Web of Science ®Google Scholar
• Goldberg I, JG C, Jasek MC, JA S, WC S; Group ASI. Intraocular pressure-lowering efficacy of brinzolamide when added to travoprost/timolol fixed combination as adjunctive therapy. J Glaucoma. 2012;21(1):55–59.
   Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120(10):1268–1279.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Knudtson MD. Intraocular pressure and systemic blood pressure: longitudinal perspective: the Beaver Dam Eye Study. Br J Ophthalmol. 2005;89(3):284–287.
   PubMed Web of Science ®Google Scholar
• Hulsman CA, Vingerling JR, Hofman A, Witteman JC, de Jong PT. Blood pressure, arterial stiffness, and open-angle glaucoma: the Rotterdam study. Arch Ophthalmol. 2007;125(6):805–812.
   Google Scholar
• Leske MC, Wu SY, Hennis A, Honkanen R, Nemesure B; Group BES. Risk factors for incident open-angle glaucoma: the Barbados Eye Studies. Ophthalmology. 2008;115(1):85–93.
   PubMed Web of Science ®Google Scholar
• Seibold LK, DeWitt PE, Kroehl ME, Kahook MY. The 24 hr effects of brinzolamide/brimonidine fixed combination and timolol on intraocular pressure and ocular perfusion pressure. J Ocul Pharmacol Ther. 2017;33(3):161–169.
   PubMed Web of Science ®Google Scholar
• Atey TM, Shibeshi W, SW A. The impact of adherence and instillation proficiency of topical glaucoma medications on intraocular pressure. J Ophthalmol. 2017;2017:1683430.
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol. 2017;176:61–69.
   PubMed Web of Science ®Google Scholar